AnastasiosManessisMD FACE, ECNU, ABOM

Endocrinology • New York, NY

Endocrine Associate of West Village PC, Medical Director

Join to view full profile

Dr. Manessis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Manessis' full profile

Already have an account?

Office
160 East 32nd Street
Suite 102
New York, NY 10016
Phone+1 212-675-9332

Fax+1 212-604-3844
Is this information wrong?

Education & Training

New York Medical College at St Vincent's Hospital and Medical Center of New YorkFellowship, Endocrinology, Diabetes, and Metabolism, 2006 - 2008
New York Medical College at St Vincent's Hospital and Medical Center of New YorkResidency, Internal Medicine/Pediatrics, 2001 - 2005
Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 2001
Manhattan CollegeBS, Biochemistry, Cum Laude, 1990 - 1994

Certifications & Licensure

NY State Medical License 2005 - 2025
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
American Board of Obesity Medicine Obesity Medicine
American Association of Clinical EndocrinologistEndocrine Certification in Neck Ultrasound

Awards, Honors, & Recognition

Fellow of American College of Endocrinology ACE, 2015
Best of Queens Queens Tribune, 2014
Most Compassionate Doctor Vitals, 2013
Americas Top Physicians Consumer Research Council of America, 2012
Honored Member Trademark Who's Who, 2012
Join now to see all

Clinical Trials

A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin Start of enrollment: 2011 Nov 01
Completed
Phase 3
Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes Start of enrollment: 2013 Feb 21
Completed
Phase 3
Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1) Start of enrollment: 2014 Jun 01
Completed
Phase 3
Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications Start of enrollment: 2015 Jan 01
Completed
Phase 3
A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus Start of enrollment: 2016 May 05
Completed
Phase 4
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period Start of enrollment: 2016 Jul 06
Completed
Phase 3
A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulins in Insulin Naïve Patients Initiating Insulin Start of enrollment: 2015 Nov 05
Completed
Phase 4
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes Start of enrollment: 2019 May 08
Active, not recruiting
Phase 3
STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity Start of enrollment: 2019 Jan 21
Completed
Phase 3
Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine Start of enrollment: 2019 Mar 11
Completed
Phase 3
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Start of enrollment: 2019 Sep 06
Completed
Phase 4
A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes Start of enrollment: 2019 Oct 01
Completed
Phase 3
A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range) Start of enrollment: 2020 Nov 04
Completed
Phase 3
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin Start of enrollment: 2022 Mar 08
Active, not recruiting
Phase 3
Pivotal Trial of a Digital Therapeutic for the Treatment of Type 2 Diabetes Start of enrollment: 2021 Apr 22
Completed
Phase 3
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy Start of enrollment: 2022 Aug 12
Active, not recruiting
Phase 3
Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia Start of enrollment: 2021 May 31
Completed
Phase 2
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk Start of enrollment: 2023 Apr 03
Recruiting
Phase 3
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes Start of enrollment: 2023 Jun 05
Active, not recruiting
Phase 3
Eversense® Non-adjunctive Use Post Approval Study Start of enrollment: 2021 Apr 13
Recruiting
Not Applicable
Evaluation of the Efficacy and Safety of Duodenal Mucosal Resurfacing Using the Revita® System in Subjects With Type 2 Diabetes on Insulin Therapy Start of enrollment: 2021 Mar 08
Recruiting
Not Applicable
Join now to see all

Publications & Presentations

PubMed

1 citations
Increased Intact Proinsulin in the Oral Glucose Challenge Sample is an Early Indicator for Future Type 2 Diabetes Development - Case Reports and Evidence from the Lite...
Andreas Pfützner, Anastasios Manessis, Mina Hanna, Jack Lewin> ;Clinical Laboratory. 2020 May 1
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T, ...> ;The New England journal of medicine. 2016-09-15
20 citations
Iatrogenic osteoporosis, bilateral HIP osteonecrosis, and secondary adrenal suppression in an HIV-infected man receiving inhaled corticosteroids and ritonavir-boosted ...
Nargess Kaviani, Phillip Bukberg, Anastasios Manessis, Vincent Yen, Iven Young> ;Endocrine Practice. 2011 Jan 1
14 citations
Quantifying amount of adsorption of levothyroxine by percutaneous endoscopic gastrostomy tubes.
Anastasios Manessis, Steven Lascher, Phillip Bukberg, Todd Darmody, Vincent Yen, Samy Sadek, Iven Young> ;JPEN. Journal of Parenteral and Enteral Nutrition. 2008 Mar 1
99 citations
Disruption of IcsP, the major Shigella protease that cleaves IcsA, accelerates actin-based motility.
Kalpana D. Shere, Sandra Sallustio, Anastasios Manessis, Teresa G. D’Aversa, Marcia B. Goldberg> ;Molecular Microbiology. 1997 Aug 1
Join now to see all

Journal Articles

(Research Participation) Randomized, Controlled Trial of a Digital Behavioral Therapeutic Application to Improve Glycemic Control in Adults With Type 2 Diabetes
Hsia J, Guthrie NL, Lupinacci P, Gubbi A, Denham D, Berman MA, Bonaca MP., Diabetes Care, 12/1/2022
(Research Participation) Randomized, Controlled Trial of a Digital Behavioral Therapeutic Application to Improve Glycemic Control in Adults With Type 2 Diabetes
Judith Hsia; Nicole L. Guthrie; Paul Lupinacci; Ananda Gubbi; Douglas Denham; Mark A. Berman; Marc P. Bonaca, Diabetes Care, 10/1/2022
(Research Participation) Cognitive behavioral therapy delivered via digital mobile application for the treatment of type 2 diabetes: Rationale, design, and baseline ch...
Mario Enrico Canonico MD, Judith Hsia MD, Nicole L. Guthrie MS, Martha Simmons MD, PhD, Prapti Mehta MD, Paul Lupinacci PhD, Kate Edwards NP, Kara Mosesso NP, Michelle..., Clinical Cardiology, 7/1/2022
(German language) Pulsatile insulin infusion therapy: a treatment option to delay dialysis Patients with type 2 diabetes and stage III renal failure
Andreas Pfützner, Anastasios Manessis et al, Diabetes, Stoffwechsel und Herz (English translation "Diabetes, Metabolism and Heart"), 2/1/2022
What Podiatrists Need to Know about Diabetes and Endocrinology
Jean Chen-Vitulli DPM, MS and Anastasios Manessis, MD, Podiatry Management Online, 8/2021
(Research Participation) Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: t...
Sun B, Sengupta N, Rao A, Donnelly C, Waichale V, Roy AS, Ramaswamy S, Pathak D, Bowsher RR, Raiter Y, Aubonnet P, Barve A., BMC Endocr Disord., 6/26/2021
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial
Domenica Rubino 1, Niclas Abrahamsson 2, Melanie Davies 3 4, Dan Hesse 5, Frank L Greenway 6, Camilla Jensen 5, Ildiko Lingvay 7, Ofri Mosenzon 8, Julio Rosenstock 9, ..., JAMA, 2021 Apr 13;325(14):1414-1425., 4/13/2021
Pulsatile Insulin Infusion as a Treatment Option for Patients with Type 2 Diabetes and Stage III Kidney Failure - Results from a Pilot Study
Manessis A1,2, Hanna MR3,4, Sachsenheimer D3, Do L2, Lewin JC4, Steiner SS4, McCormack S4, Demircik F5 and Pfützner A3,4,6*, EC ENDOCRINOLOGY AND METABOLIC RESEARCH, 3/31/2021
Randomized Double-Blind Clinical Trial Comparing Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes: PRONTO-T2D
Blevins Thomas, Diabetes Care, 7/2/2020
(Research Participation) Efficacy and safety of MYL-1501D vs insulin glargine in patients with type 1 diabetes after 52 weeks: Results of the INSTRIDE 1 phase III study
Blevins TC, Barve A, Sun B, Ankersen M., Diabetes Obes Metab., 8/1/2018
(Research Participation) Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert. SUSTAIN-6 Investigators, The New England journal of medicine, 9/15/2016
Join now to see all

Abstracts/Posters

A case of pediatric papillary thyroid carcinoma in an 8 year-old Venezuelan female.
N.M. Fanaropoulou1, M. Moncada2, A. Manessis 3,4, WCTC June 2023, 6/2023
Next Generation Sequencing testing for genetic causes of refractory hypertriglyceridemia in an outpatient endocrine clinic: A case series
Panagiotis Theodoropoulos, Anastasios Manessis, AACE Annual Meeting 2023, 5/4/2023
Case study: A challenging Case of Management of Pre-existing Type 2 Diabetes Mellitus During Pregnancy in a Patient with Multiple Insulin Allergies
Daiena Shahid, Anastasios Manessis, Endocrine Practice (supplement to AACE's journal), 5/4/2023
Clinical Management of a Trauma Wound in Diabetic Patient with a Synthetic Hybrid-Scale Fiber Matrix*
Anthony Iorio, DPM, MPH; Jean Chen-Vitulli, DPM, MS; Endocrine Associates of West Village, SAWC Spring 2023, 4/26/2023
Application of a Synthetic Hybrid-Scale Fiber Matrix* in a Diabetic Foot Ulcer
Anthony Iorio, DPM, MPH; Jean Chen-Vitulli, DPM, MS; Endocrine Associates of West Village, SAWC Spring 2023, 4/26/2023
Use of Bioresorbable Silver Matrix on Non-Healing TMA Site
Anthony Iorio, DPM, MPH; Jean Chen-Vitulli, DPM, MS; Anastasios Manessis, MD, n/a
Case of Pembrolizumab Induced Type 1 Diabetes Mellitus
Stavroula Spyropoulos, Anastasios Manessis M.D. New York University, Department of Endocrinology, New York University Grossman School of Medicine, ADA 2021, Virtual, 6/18/2021
Pulsatile Insulin Treatment as a Treatment Option for Patients with Type 2 Diabetes and Stage 3 Kidney Failure
Sophia Quach, Anastasios Manessis, Diabetes, Diabetes 2021;70(Supplement_1):112-LB, 6/1/2021
De-Escalation Therapy (DET) - An intensive short-term temporary pharmacological intervention to stop disease progression in patients with Type 2 diabetes.
Pfutzner A., Lewin J., Do L., Liu J., Demircik F., Manessis A., Pfutzner Science and Health, Mainz Germany;, Upon Request - 11/2020, 11/2020
Pulsatile Insulin Treatment as a Treatment Option for Patients with Type 2 Diabetes and Stage III Kidney Failure - Results from a Pilot Study
Pfutzner A., Hanna MR, Sachsenheimer D., Andor Y., Do L., Steiner SS, McCormmak S. Manessis A., Diakard, Inc., Upon Request, 11/2020
Clinical Application of Synthetic Hybrid-Scale Wound Matrix* in the Treatment of a Chronic, Hard to Heal Wound of the Lower Extremity: A Case Report
Anthony Iorio, DPM, MPH; Jean Chen-Vitulli, DPM, MS; Endocrine Associates of West Village, SAWC Spring 2023, 4/26/2013
Thyrotoxic Periodic Paralysis
E.Walsh, A.Manessis, I Young, American College of Physicians , New York Chapter Poster Presentation, New York, New york, 3/24/2007
Join now to see all

Press Mentions

What Podiatrists Need to Know About Diabetes and Endocrinology.August 1st, 2021
Inhalable Insulin Offers New Approach to Diabetes TreatmentJanuary 10th, 2017

Professional Memberships

American Association of Clinical Endocrinologists - AACE
Member
American Association of Clinical Endocrinologists - AACE
Fellow
American Thyroid Association - ATA
Member
American Podiatric Medical Association - APMA
Member
American Diabetes Association - ADA
Member
American Institute of Ultrasound in Medicine - AIUM
Member
American Medical Association - AMA
Member
The Obesity Association
Member
The Endocrine Society
Member

Other Languages

Greek, Spanish

Hospital Affiliations

NewYork-Presbyterian/Lower Manhattan HospitalNew York, New York
NYU Langone Orthopedic HospitalNew York, New York
NYU Langone HospitalsNew York, New York
Mount Sinai Hospital of QueensAstoria, New York
New York-Presbyterian HospitalNew York, New York

External Links

Facebookhttps://www.facebook.com/anastasios.manessis.5
Facebookhttps://www.facebook.com/Endocrine-Associate-of-West-Village-PC-1411528985815618/
Instagramhttps://www.instagram.com/dr.manessis/